Ashish Kacholia's Portfolio multibagger Stock: This small-cap company receives marketing approval from 4 countries for its oncology product!
The stock is up by 50 per cent in 6 months and generated multibagger returns of over 300 per cent in just 3 years.
Venus Remedies Limited announced that the company is making rapid strides in the oncology space by expanding its global reach. Venus Remedies Ltd, a well-known provider of affordable cancer drugs worldwide, has further consolidated its position in the Gulf Cooperation Council (GCC), Association of South East Asian Nations (ASEAN), Balkan and Caribbean regions with marketing approvals from Oman, Malaysia, Bosnia and Trinidad & Tobago for key chemotherapy drugs.
While Venus Remedies has secured marketing approval for pemetrexed from Malaysia, one of the largest markets in the ASEAN region, it has reached important regulatory milestones with product registration for docetaxel in Oman, gemcitabine in Bosnia and carboplatin, bortezomib and docetaxel in Trinidad & Tobago. The company remain steadfast in our commitment to providing access to life-saving treatment to more and more patients in keeping with our mission of meeting unmet medical needs in oncology and other critical care segments.
The USD 2.8 billion pharmaceutical markets of Malaysia, a growing market for cancer drugs where Venus Remedies has so far secured marketing approval for 27 products across various segments, presents immense opportunities for the company to expand its operations in the Asia-Pacific region in general and Southeast Asia in particular through its elaborate range of drugs. With this, the company has secured 503 marketing approvals for its oncology products across 75 countries.
Want more insightful stories along with recommendations?
Get a 3-month subscription to experience the power of our flagship DSIJ Magazine (online edition) for just Rs 800/- Click here to subscribe now
On Friday, shares of Venus Remedies Ltd gained 3 per cent to Rs 260.80 per share with an intraday high of Rs 261.95 and an intraday low of Rs 243.05. The shares of the company saw a spurt in volume by more than 1.40 times on BSE. The stock has a PE of 12.03x whereas the sectoral PE is 25.50x.
Ashish Kacholia, an ace investor owns stakes in this company. The stock is up by 50 per cent in 6 months and generated multibagger returns of over 300 per cent in just 3 years. Investors should keep an eye on this stock.